Helsinn Group and Chugai Pharma Europe Renew Their Collaboration to Distribute AKYNZEO® in the UK and Ireland
Thursday, June 13, 2024
Helsinn Group, a global pharmaceutical company with over 45 years of experience in supportive care, oncology, and dermato-oncology, along with Chugai Pharma Europe Ltd, the European subsidiary of Chugai Pharmaceutical Co, Ltd., a leading pharmaceutical company from Japan, have renewed their Distribution and Licence Agreement in the United Kingdom and Republic of Ireland for AKYNZEO® (a combination of netupitant and palonosetron), which is used to prevent chemotherapy-induced nausea and vomiting (CINV) in adults.
Chugai Pharma Europe, stated, “We are thrilled to continue our partnership with Helsinn. Oncology is a key focus for us, and this renewal highlights our dedication to improving cancer care. Together with Helsinn, we aim to ensure that patients in the UK and Ireland have access to AKYNZEO®, an important supportive care medication.”
Helsinn Group, added, “Renewing our agreement with Chugai is a significant step forward. Chugai has been an excellent partner for the past ten years, and our shared commitment to supportive care will enhance our efforts to improve the quality of life for cancer patients in this critical market. We are eager to explore the new opportunities this partnership will bring as we strengthen our existing foundation.”
AKYNZEO® is the only fixed combination of 5-HT3 and NK1 receptor antagonists approved for adults to prevent both acute and delayed nausea and vomiting caused by highly and moderately emetogenic chemotherapy.
Source: globenewswire.com
